

DES/HXC
February 2, 2011



PATENT APPLICATION
Docket No.: 3518.1015-000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Thomas M. DiMauro, Mohamed Attawia, Hassan Serhan, Martin A. Reynolds, Melissa Grace, Sudhakar Kadiyala, David Urbahns, Scott Bruder, Gregory Collins, Laura J. Brown, Jeff Geesin, Pamela L. Plouhar, Catherine Smith and John Siekierka

Application No.: 10/630,227 Group: 1647

Filed: July 30, 2003 Examiner: Shulamith H. Shafer

Confirmation No.: 8291

For: TRANS-CAPSULAR ADMINISTRATION OF HIGH SPECIFICITY CYTOKINE INHIBITORS INTO ORTHOPEDIC JOINTS

CERTIFICATE OF MAILING OR TRANSMISSION	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or is being facsimile transmitted to the United States Patent and Trademark Office on:	
02/02/11	Signature
Date	
Hak J. Chang	
Typed or printed name of person signing certificate	

REPLY TO ELECTION/RESTRICTION REQUIREMENT AND AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Responsive to the Election Requirement dated December 2, 2010, Applicants hereby provisionally elect, with traverse, BMP-7 and infliximab as the species for prosecution. Applicants reserve the right to file a continuing application or take such other appropriate action as deemed necessary to protect the non-elected inventions. Applicants do not hereby abandon or waive any rights in the non-elected inventions. Claims readable on the elected species are Claims 1-2, 34, 36-43, 45-48, 50, 51, 53-58, 60-65, 91 and 96.

An extension of time to respond to the Restriction Requirement is respectfully requested. A Petition for an Extension of Time and the appropriate fee are being filed concurrently.

Please amend the application as follows: